Bispecific antibody complex pre-targeted delivery of polymer-drug conjugates for cancer therapy

Drug Delivery and Translational Research

Volumn 2, Issue 1, 2012, Pages 65-76

  Gada, Keyur S ^a   Patil, Vishwesh ^a   Panwar, Rajiv ^a   Hatefi, Arash ^b   Khaw, Ban An ^a  

^a NORTHEASTERN UNIVERSITY   (United States)

^b RUTGERS UNIVERSITY   (United States)

Author keywords

Bispecific antibody complex; Cardiotoxicity; Doxorubicin; HER2 neu; Polymer prodrug conjugates; Pretargeting

Indexed keywords

AMIDE; BISPECIFIC ANTIBODY; DOXORUBICIN; IMMUNOGLOBULIN F(AB) FRAGMENT; PENTETIC ACID; POLYGLUTAMIC ACID; PRODRUG; SULFIDE;

AMINO TERMINAL SEQUENCE; ANIMAL CELL; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER THERAPY; CARDIOTOXICITY; CELL KILLING; CONJUGATE; CONJUGATION; CONTROLLED STUDY; COVALENT BOND; DRUG DELIVERY SYSTEM; EMBRYO; EMBRYOTOXICITY; EPIFLUORESCENCE MICROSCOPY; FLUORESCENCE; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; NONHUMAN; ONCOGENE NEU; PRIORITY JOURNAL; RAT;

EID: 84865483799     PISSN: 2190393X     EISSN: 21903948     Source Type: Journal    
DOI: 10.1007/s13346-011-0055-x     Document Type: Article

References (37)

1. Chabner BA, Roberts TG. Chemotherapy and the war on cancer. Nature Reviews Cancer. 2005;5:65-72.
2. Von Hoff DD, Rozencweig M, Piccart M. The cardiotoxicity of anticancer agents. Seminars in Oncology. 1982;9:23-33.
3. Singal P, Iliskovic N, Li T, Kumar D. Adriamycin cardiomyopathy: pathophysiology and prevention. FASEB Journal. 1997;11:931-6.
4. Injac R, et al. Acute doxorubicin nephrotoxicity in rats with malignant neoplasm can be successfully treated with fullerenol C60(OH)24 via suppression of oxidative stress. Pharmacol Rep. 2008;60:742-9.
5. Bulucu F, et al. Effects of N-acetylcysteine, deferoxamine and selenium on doxorubicin-induced hepatotoxicity. Biol Trace Elem Res. 2009;132:184-96.
6. Duncan R, et al. Preclinical evaluation of polymer bound doxorubicin. J Cont Rel. 1992;19:331-46.
7. Ringsdorf H. Structure and properties of pharmacologically active polymers. J Polym Sci. Polymer Symposia. 1975;51:135-153.
8. Van Heeswijk WAR, et al. The synthesis and characterization of polypeptide-adriamycin conjugates and its complexes with adriamycin. J Cont Rel. 1985;1:301-15.
9. Li C. Poly (L-glutamic acid)-anticancer drug conjugates. Advanced Drug Delivery Reviews. 2002;54:695-713.
10. Hoes CJT, Potman W, van Heeswijk WAR, Mud J, de Grooth BG, Greve J, Feijen J. Optimization of macromolecular prodrugs of the antitumor antibiotic adriamycin. J Cont Rel. 1985;2:205-13.
11. Li C, et al. Complete regression of well established tumors using novel water-soluble poly(L-glutamic acid)-paclitaxel conjugates. Cancer Res. 1998;58:2404-9.
12. Singer JW, et al. Conjugation of camptothecins to poly(L-glutamic acid). Ann NY Acad Sci. 2000;922:136-50.
13. Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent SMANCS. Cancer Research. 1986;46:6387-92.
14. Hughes B. Antibody-drug conjugate for cancer: poised to deliver? Nat Rev Drug Discov. 2011;9:665-7.
15. Narula J, Torchilin VP, Petrov A, Khaw S, Trubetskoy VS, O'Donnell SM, et al. In vivo targeting of acute myocardial infarction with negative-charge, polymer-modified antimyosin antibody: use of different cross-linkers. J of Nucl Cardiol. 1995;2:26-34.
16. Haeuw JF, Caussanel V, Beck A. Immunoconjugates, drug-armed antibodies to fight against cancer. Med Sci (Paris). 2009;25:1046-52.
17. Senter PD, Springer CJ. Selective activation of anti-cancer prodrugs by monoclonal antibody-enzyme conjugates. Adv Drug Deliv Rev. 2001;53:247-64.
18. McBride WJ, et al. Bispecific antibody pretargeting PET (ImmunoPET) with an 124I-labeled hapten-peptide. J Nucl Med. 2006;47:1678-88.
19. Goodwin DA. Strategies for antibody targeting. Antibody, Immunoconjugates and Radiopharm. 1991;4:427-34.
20. Fury MG, Lipton A, Smith KM, Winston CB, Pfister DG. A phase-I trial of the epidermal growth factor receptor directed bispecific antibody MDX-447 without and with recombinant human granulocyte-colony stimulating factor in patients with advanced solid tumors. Cancer Immunol Immunother. 2008;57:155-63.
21. Gada KS, Patil V, Panwar R, Majewski S, Tekabe Y, Khaw BA. Pretargeted gamma imaging of murine metastatic melanoma lung lesions with bispecific antibody and radiolabeled polymer drug conjugates. Nuclear Medicine Communications. 2011;32:1231-40.
22. Patil V, et al. Imaging prostate cancer PC-3 xenografts with In-111- polymer-drug conjugates after pretargeting with Bombesinbispecific antibody complexes. J Nucl Med. 2010;51:111P.
23. Khaw BA, Rammohan R, Abu-Taka A. Bispecific enzyme-linked signal-enhanced immunoassay with subatto moles sensitivity. Assay Drug Dev Technol. 2005;3:319-27.
24. Stahl S, et al. Selection and characterization of HER2/neu-binding affibody ligand. Protein Engineering, Design & Selection. 2004;17:455-62.
25. Canine BF, Wang Y, Arash H. Biosynthesis and characterization of a novel genetically engineered polymer for targeted gene transfer to cancer cells. J Control Release. 2009;138:188-96.
26. Nilsson FY, et al. Tumor imaging using a picomolar affinity HER2 binding affibody molecule. Cancer Res. 2006;66:4339-48.
27. Capala J, et al. Affibody molecules for in vivo characterization of HER2-positive tumors by near-infrared imaging. Clin Cancer Res. 2008;14:3840-9.
28. Trubetskoy V, et al. Chemically optimized antimyosin fab conjugates with chelating polymers: importance of the nature of the protein-polymer single site covalent bond for biodistribution and infarction localization. Bioconjugate Chem. 1993;4:251-5.
29. Khaw BA, Tekabe Y, Johnson LL. Imaging experimental atherosclerotic lesions in ApoE knockout mice: enhanced targeting with Z2D3-anti-DTPA bispecific antibody and 99mTc-labeled negatively charged polymers. J Nucl Med. 2006;47:868-76.
30. Bernatowicz MS, Matsueda GR. Preparation of peptide-protein immunogens using N-succinimidyl bromoacetate as a heterobifunctional crosslinking reagent. Analytical Biochemistry. 1986;155:95-102.
31. Habeeb AFSA. Determination of free amino groups in proteins by trinitrobenzenesulfonic acid. Anal Biochem. 1966;14:328-36.
32. Arnold RD, Slack JE, Straubinger RM. Quantification of doxorubicin andmetabolites in rat plasma and small volume tissue samples by liquid chromatography/electrospray tandemmass spectroscopy. Journal of Chromatography B. 2004;808:141-52.
33. Strober W. Trypan blue exclusion test of cell viability. In: Coligan JE., Kruisbeck AM., Margulies DH., Shevach EM, Strober W. (Eds.), Current Protocols in Immunology, Wiley, New York, 1997. Appendix 3B.
34. Putz G, Schmah O, Eckes J, Hug MJ, Winkler K. Controlled application and removal of liposomal therapeutics: effective elimination of pegylated liposomal doxorubicin by double-filtration plasmapheresis in vitro. Journal of Clinical Apheresis. 2010;25:54-62.
35. Khaw BA, Narula J, Strauss HW. Monoclonal Antibodies in Cardiovascular Diseases. In: Lea and Febiger, Malvern, Pennsylvania, 1994; pp. 268-283.
36. Kim SJ, Park Y, Hong HJ. Antibody engineering for the development of therapeutic antibodies. Mol Cells. 2005;20:17-29.
37. Gada K, Patil V, Khaw B, et al. Enhanced targeted tumorotoxicity and reduced cardiotoxicity with bispecific antibody-polymer-prodrug complexes: in vitro studies with BT-20 human breast carcinoma and embryonic cardiocytes. Poster presented at: 35th Annual Meeting & Exposition of the Controlled Release Society; July 13-16, 2008; New York, NY